Paragraph IV Certifications: How Generic Drug Makers Legally Challenge Patents
Paragraph IV certifications let generic drug makers legally challenge brand-name patents before launch. This Hatch-Waxman Act tool saves billions in drug costs and creates a 180-day exclusivity window for the first challenger-making it the most powerful path to market for generics.